Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They discuss the challenges of developing products that counter diseases and ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Investing.com -- Eli Lilly and Company (NYSE: LLY) CEO David Ricks spoke to the BBC about the long-term effects of the Trump administration’s sweeping tariffs on imports, in the first comments from a ...

In January, Eli Lilly CEO Dave Ricks said the pill could receive U.S. regulatory approval as soon as early 2026. The company also said in its annual report in February it recorded a nearly $550 ...

One of them is the pharmaceutical industry. However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter!